Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edivoxetine vs Placebo in Major Depressive Disorder
NCT00795821Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing LY2216684 with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 10 weeks. Started Dec 2008; status: completed.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00795821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00795821.